PML::RARA t(15;17)
Multiplex RQ-PCR detection of PML::RARA fusion transcripts (long, variant, short isoforms) for acute promyelocytic leukemia diagnosis and monitoring. STAT testing available.
RBM15::MRTFA t(1;22)
Quantitative RQ-PCR detection of RBM15::MRTFA (MKL1) fusion transcripts from the t(1;22) translocation.
RUNX1::RUNX1T1 (AML1-ETO) t(8;21)
Quantitative RQ-PCR detection of RUNX1::RUNX1T1 (AML1::ETO) fusion from t(8;21), associated with favorable prognosis in AML.
TCF3::PBX1 (E2A::PBX1) t(1;19)
Quantitative RQ-PCR detection of TCF3::PBX1 (E2A::PBX1) fusion from t(1;19) for ALL diagnosis and minimal residual disease monitoring.
ETV6::RUNX1 t(12;21)
Quantitative RQ-PCR detection of the t(12;21) ETV6::RUNX1 (TEL::AML1) fusion, associated with favorable prognosis in ALL.
FIP1L1::PDGFRA del(4q12)
Quantitative RQ-PCR detection of the FIP1L1::PDGFRA fusion from interstitial 4q12 deletion in HES and chronic eosinophilic leukemia.
ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RQ-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
CBFA2T3::GLIS2
Quantitative RQ-PCR detection and monitoring of the inv(16)(p13.3q24.3) CBFA2T3::GLIS2 fusion in AML with RAM immunophenotype.
CBFB::MYH11 inv(16) or t(16;16)
Quantitative RQ-PCR detection and monitoring of CBFB::MYH11 fusion transcripts (types A, D, E) from inv(16)/t(16;16) in AML.
